Highlights from ASCO 2025—advances in the treatment of ovarian cancer
The ASCO 2025 session highlighted that primary cytoreductive surgery improves progression‑free survival, that adding the PD‑1 inhibitor dostarlimab to chemotherapy modestly improves PFS, and that combining relacorilant with nab‑paclitaxel significantly improves survival in platinum‑resistant ovarian cancer.
This short review summarizes key findings from the TRUST, FIRST, and ROSELLA trials presented at ASCO 2025, covering optimal timing of surgery, emerging use of immunotherapy, and novel treatments for platinum‑resistant ovarian cancer, and discusses their potential impact on clinical practice.
These findings may guide clinicians toward personalized surgical timing, suggest incorporating checkpoint inhibitors into first‑line therapy, and provide a new effective regimen for platinum‑resistant disease, potentially improving overall survival and quality of life for ovarian cancer patients.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements